FYI
Stock #1: ACADIA Pharmaceuticals Inc. (ACAD)ACAD is a biopharmaceutical company that focuses on developing and commercializing innovative medicines to address unmet medical needs in central nervous system (CNS) disorders and rare diseases. ACAD is valued at $2.65 billion by market cap.On April 22, 2024, ACAD announced that Health Canada has accepted its New Drug Submission for Trofinetide, intended for the treatment of Rett syndrome, and has granted it Priority Review. If approved, Trofinetide will be the first treatment option for Rett syndrome available in Canada.In terms of the trailing-12-month levered FCF margin, ACAD's 4.23% is 227.8% higher than the 1.29% industry average. Moreover, the stock's 1.08x trailing-12-month asset turnover ratio is 166.1% higher than the 0.40x industry average.For the fiscal first quarter that ended on March 31, 2024, ACAD's total revenues increased 73.7% year-over-year to $205.83 million. Its income from operations amounted to $15.21 million, compared to a loss from operations of $53.58 million in the previous year's quarter.For the same quarter, ACAD's net income and EPS stood at $16.56 million and $0.10, respectively, compared to a net loss and net loss per share of $43.02 million and $0.27 in the year-ago quarter, respectively. As of March 31, 2024, its cash, cash equivalents, and investment securities stood at $470.50 million compared to $438.90 million as of December 31, 2023.Analysts expect ACAD's EPS for the quarter ended June 30, 2024, to increase considerably year-over-year to 0.19. Its revenue for the same is expected to grow 42.6% year-over-year to $235.58 million.Over the past month, the stock has gained 6.2% to close the last trading session at $16.04. The average analyst price target of $27.36 indicates a 70.6% upside potential.ACAD's POWR Ratings reflect its solid prospects. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system.ACAD has an A grade for Growth and a B for Value and Quality. Within the Medical – Pharmaceuticals industry, it is ranked #13.
- Forums
- ASX - By Stock
- NEU
- Acadia
Acadia, page-630
-
-
- There are more pages in this discussion • 210 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.92 |
Change
0.130(0.94%) |
Mkt cap ! $1.779B |
Open | High | Low | Value | Volume |
$13.66 | $14.03 | $13.46 | $11.10M | 803.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1608 | $13.91 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.99 | 250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1608 | 13.910 |
3 | 7454 | 13.890 |
1 | 1087 | 13.880 |
1 | 2366 | 13.860 |
1 | 2366 | 13.840 |
Price($) | Vol. | No. |
---|---|---|
14.040 | 1608 | 2 |
14.050 | 2366 | 1 |
14.070 | 2366 | 1 |
14.100 | 2366 | 1 |
14.120 | 2859 | 2 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |